In this edition of AcademyHealth’s Situation Report, we examine key federal actions that could reshape vaccine access, the future health research workforce, and core pillars of the U.S. evidence enterprise. A CDC advisory committee’s vote to roll back the universal hepatitis B birth-dose recommendation has drawn strong objections from clinical and public health experts. At the same time, new federal student loan caps and a narrowed definition of “professional degree” could reduce access to graduate training across many health-related fields. We also summarize developments affecting SNAP administrative funding, proposed changes to FDA drug trial expectations, the congressional outlook for ACA subsidies, and new NIH policies that raise concerns about stability and transparency in federal research funding.
In this issue:
- CDC Panel Votes to Narrow Long-Standing Hepatitis B Birth Vaccine Recommendation
- New Blog Post Examines How Federal Loan Caps Could Reshape the Health Research Workforce
- Former FDA Commissioners Express Concern Over Proposed Vaccine Regulations
- USDA’s Data Mandate Puts SNAP Administrative Funding at Risk
- FDA to Change Clinical Trial Requirements, Lowering Regulatory Standards for New Drugs
- Big ACA Reforms Pushed to 2026, Senate Expected to Vote on Subsidies Next Week
- Recent NIH Policies Give Political Appointees More Power to Terminate and Award Grants
CDC Panel Votes to Narrow Long-Standing Hepatitis B Birth Vaccine Recommendation
CDC’s Advisory Committee on Immunization Practices (ACIP) voted this week to scale back the universal hepatitis B vaccine recommendation for newborns, a policy in place for more than 30 years and widely credited with major reductions in pediatric hepatitis B infections. The panel recommended limiting the birth-dose to infants whose mothers test positive for the virus, and advising parents of other newborns to discuss vaccination with their clinicians. Many pediatric and infectious-disease experts objected, citing the strong evidence behind the universal birth-dose strategy and warning that the change could increase preventable infections. Members also split on a proposal to move away from the standard three-dose regimen, despite a lack of data supporting fewer doses.
For the health services research community, the decision underscores the importance of transparent, evidence-based policymaking, strong vaccine-effectiveness data, and careful evaluation of downstream impacts on public health outcomes and health inequities. Researchers may be called on to assess how shifts in long-standing immunization policy affect disease burden, clinical practice, and trust in public health systems.
New Blog Post Examines How Federal Loan Caps Could Reshape the Health Research Workforce
A new AcademyHealth blog post highlights how H.R. 1 and related regulatory proposals would significantly restrict federal borrowing for many advanced degrees—including nursing, public health, social work, allied health, biostatistics, health policy, and other fields central to the health services research ecosystem. The Department of Education is considering a much narrower definition of “professional degree,” which would exclude most research-focused and practice-oriented master’s and doctoral programs from higher borrowing limits. The change would also impose strict annual, aggregate, and lifetime caps and eliminate Graduate PLUS loans beginning in 2026.
According to the post, these shifts could disproportionately harm nontraditional and part-time students—many of whom work in health systems, public health agencies, or community-based settings—by limiting access to affordable graduate training. For the health services research community, the implications are far-reaching: a constrained pipeline of future researchers and clinician-researchers, reduced workforce diversity, and fewer cross-disciplinary practitioners equipped to support quality, safety, health equity, and evidence-based policymaking. The blog urges stakeholders to engage in the upcoming federal comment period to help ensure that borrowing policies support, rather than hinder, the nation’s scientific and health workforce.
Former FDA Commissioners Express Concern Over Proposed Vaccine Regulations
Twelve former commissioners of the FDA, spanning administrations of both parties, issued a perspective piece in the New England Journal of Medicine warning that the agency’s vaccine regulation plans represent a threat to effective, available vaccines and public health. A recent memo leaked by Vinay Prasad, the agency’s top regulator of vaccines, described the changes as a move to upend core policies governing vaccine developments. These changes come from the identification in which 10 cases where COVID vaccines were allegedly tied to child death. In the perspective piece, the former commissioners identified that this conclusion contradicts previous reviews and lacks transparent methodology. The commissioners warn that proposed changes, such as eliminating reliance on immune-response data and demanding larger randomized trials for vaccine updates could hamper timely updates to respiratory virus vaccines and flexible responses to evolving pathogens—ultimately delaying or restricting access to immunizations. Further, the commissioner expressed concerns about agency’s current lack of engagement with expert advisory committees. For health services researchers, this signals a potential pivot in regulatory strategy that could reshape the balance between scientific rigor, update speed, and access to vaccines.
USDA’s Data Mandate Puts SNAP Administrative Funding at Risk
The Trump administration is planning to withhold federal administrative funding from states that refuse to provide detailed data on SNAP recipients, including immigration status and other personal information. The USDA claims the data is necessary to identify cases of fraud. This request was initially made in February, but 22 states and the District of Columbia sued the agency, arguing that these data demands violate privacy protections and exceed the agency’s authority. A federal judge has barred the administration from collecting the information from those states. As of this week, the USDA Secretary Brooke Rollins said that action will be taken against the states that have yet to comply. If states do not share data by December 8th, the USDA will pull their administrative funds. While the funds targeted are not individuals’ SNAP benefits, for health services researchers this data-sharing mandate introduces concerns for state capacity to maintain these essential programs for low-income populations.
FDA to Change Clinical Trial Requirements, Lowering Regulatory Standards for New Drugs
The Food and Drug Administration (FDA) Commissioner Marty Makary reported that the FDA will be changing regulatory requirements for new drugs, lowering the previously required two clinical trials to one. While Makary claims that one trial, if “designed and controlled appropriately,” is sufficient. Agency sources and experts have expressed concern and confusion by this change. According to professor of medicine and member of the Center for Bioethics at Harvard Medical School Aaron Kesselheim, it is unclear what the change would accomplish outside of “ratchet down the expectation that the FDA will seek high quality trials for the drugs that are being approved.” According to other anonymous experts, the change is “not legally sound, and its scientifically concerning.”
Moreover, anonymous sources at the FDA’s drugs center have claimed that this change has influenced top drug regulator Richard Pazdur’s decision to abruptly retire. The FDA recently announced that Tracy Beth Høeg would replace Pazdur. This change has far reaching consequences for the fields of public health and health services research as federal agencies become increasingly deregulated and the safety and efficacy of drug developments become unclear. Without a strict regulatory framework from the federal agencies we have historically relied on, it will be difficult to discern which drug developments are safe before they reach large populations. Health services researchers can communicate their concerns to policymakers and the public, helping the public discern between drugs that had a strict quality assurance and design process and those that did not.
Big ACA Reforms Pushed to 2026, Senate Expected to Vote on Subsidies Next Week
Larger health care reforms are off the table for 2025, according to Senator Bill Cassidy (R-La.), Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP). Cassidy stated that the focus should be on passing a bipartisan measure within the next three weeks, and bigger ideas on health care reform can be discussed in the new year. Meanwhile, Cassidy proposed substantial changes to fund health savings accounts for those who buy high-deductible plans on the ACA Marketplace in place of a simple extension of the health care subsidies. Senate Majority Leader John Thune (R-S.D.) promised Democrats a vote for next week on their bill addressing ACA tax credits, which is expected to be a clean extension measure. The legislation is likely to be rejected by Republicans, and it’s unclear whether Republicans will introduce a path to extend ACA tax credits or another way to address health care affordability in the short term.
Recent NIH Policies Give Political Appointees More Power to Terminate and Award Grants
A new NIH policy, effective December 1, requires all grant award notices to inform recipients that the award can be terminated at the agency’s discretion if it “determines that the award no longer effectuates the program goals or agency priorities.” Experts and researchers warn that the policy creates uncertainty, makes it much more difficult to do science, and raises ethical concerns, especially when recruiting study participants. This change comes shortly after NIH announced a change in policy related to the process for awarding decisions. The agency is moving away from "paylines,” or the process of awarding grants based on peer review scores from peer review “study sections” and advisory councils, with award decisions made by the institute director with input from program officers. The use of paylines was optional, and about half of NIH’s institutes or centers followed the process. Experts warn that this change could lead NIH institute and center directors to make decisions based on political considerations rather than scientific and merit-based criteria. Such policies with the potential to politicize science complicate the process of obtaining federal funding, conducting federally funded research, and producing sound science.
Previous Editions
This is the latest in a series of Situation Report updates from AcademyHealth. You can find prior issues here.
We’re pleased to offer this work as a free resource, and if you’d like to support our efforts to keep it going, we’d truly appreciate your donation. You can contribute here. Thank you for your support!